Literature DB >> 24748336

The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein--a well-known, yet poorly understood drug transporter.

Maen Zeino1, Mohamed E M Saeed, Onat Kadioglu, Thomas Efferth.   

Abstract

P-glycoprotein is the most crucial membrane transporter implicated in tumor resistance. Intensive efforts were paid to elucidate the complex mechanism of transport and to identify modulators of this transporter. However, the borderline between substrates and modulators is very thin and identification of the binding sites within P-glycoprotein is complex. Herein, we provide an intensive review of those issues and use molecular docking to assess its ability: first, to differentiate between three groups (substrates, modulators and non-substrates) and second to identify the binding sites. After thorough statistical analysis, we conclude despite the various challenges that molecular docking should not be underestimated as differences between the distinct groups were significant. However, when it comes to defining the binding site, care must be taken, since consensus throughout literature could not be reached.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24748336     DOI: 10.1007/s10637-014-0098-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  33 in total

1.  Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil.

Authors:  T W Loo; D M Clarke
Journal:  J Biol Chem       Date:  2001-02-14       Impact factor: 5.157

Review 2.  The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding.

Authors:  Suresh V Ambudkar; In-Wha Kim; Di Xia; Zuben E Sauna
Journal:  FEBS Lett       Date:  2005-12-22       Impact factor: 4.124

3.  Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach.

Authors:  Yong-Hua Wang; Yan Li; Sheng-Li Yang; Ling Yang
Journal:  J Chem Inf Model       Date:  2005 May-Jun       Impact factor: 4.956

4.  Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Biol Chem       Date:  2003-02-27       Impact factor: 5.157

5.  Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein.

Authors:  Tip W Loo; David M Clarke
Journal:  J Biol Chem       Date:  2002-09-09       Impact factor: 5.157

6.  Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox.

Authors:  Chuanxi Cai; Hua Zhu; Jianwen Chen
Journal:  Biochem Biophys Res Commun       Date:  2004-07-30       Impact factor: 3.575

7.  Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.

Authors:  Helen M Coley
Journal:  Methods Mol Biol       Date:  2010

8.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

9.  Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.

Authors:  Tripta Bansal; Manu Jaggi; Roop K Khar; Sushama Talegaonkar
Journal:  J Pharm Pharm Sci       Date:  2009       Impact factor: 2.327

10.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

Authors:  Cheol-Hee Choi
Journal:  Cancer Cell Int       Date:  2005-10-04       Impact factor: 5.722

View more
  17 in total

1.  Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy.

Authors:  Ean-Jeong Seo; Thomas Efferth
Journal:  Oncotarget       Date:  2016-03-29

2.  Classification of P-glycoprotein-interacting compounds using machine learning methods.

Authors:  Veda Prachayasittikul; Apilak Worachartcheewan; Watshara Shoombuatong; Virapong Prachayasittikul; Chanin Nantasenamat
Journal:  EXCLI J       Date:  2015-08-19       Impact factor: 4.068

3.  Mode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (Nelumbo nucifera) against Multidrug-Resistant Tumor Cells.

Authors:  Onat Kadioglu; Betty Y K Law; Simon W F Mok; Su-Wei Xu; Thomas Efferth; Vincent K W Wong
Journal:  Front Pharmacol       Date:  2017-05-05       Impact factor: 5.810

4.  Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein.

Authors:  Hongping Min; Miaomiao Niu; Weilin Zhang; Jia Yan; Jiachang Li; Xiying Tan; Bo Li; Mengxiang Su; Bin Di; Fang Yan
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

5.  Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro.

Authors:  Onat Kadioglu; Ariel Chan; Alena Cong Ling Qiu; Vincent Kam Wai Wong; Vanessa Colligs; Sabine Wecklein; Halima Freund-Henni Rached; Thomas Efferth; Wen-Luan Wendy Hsiao
Journal:  Front Pharmacol       Date:  2017-10-09       Impact factor: 5.810

6.  Impact of NR1I2, adenosine triphosphate-binding cassette transporters genetic polymorphisms on the pharmacokinetics of ginsenoside compound K in healthy Chinese volunteers.

Authors:  Luping Zhou; Lulu Chen; Yaqin Wang; Jie Huang; Guoping Yang; Zhirong Tan; Yicheng Wang; Jianwei Liao; Gan Zhou; Kai Hu; Zhenyu Li; Dongsheng Ouyang
Journal:  J Ginseng Res       Date:  2018-04-28       Impact factor: 6.060

7.  Search for ABCB1 Modulators Among 2-Amine-5-Arylideneimidazolones as a New Perspective to Overcome Cancer Multidrug Resistance.

Authors:  Aneta Kaczor; Márta Nové; Annamária Kincses; Gabriella Spengler; Ewa Szymańska; Gniewomir Latacz; Jadwiga Handzlik
Journal:  Molecules       Date:  2020-05-11       Impact factor: 4.411

8.  P-glycoprotein transporter in drug development.

Authors:  Veda Prachayasittikul; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2016-02-12       Impact factor: 4.068

9.  Repurposing of Bromocriptine for Cancer Therapy.

Authors:  Ean-Jeong Seo; Yoshikazu Sugimoto; Henry Johannes Greten; Thomas Efferth
Journal:  Front Pharmacol       Date:  2018-10-08       Impact factor: 5.810

10.  Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds.

Authors:  Lisa Gruber; Sara Abdelfatah; Tony Fröhlich; Christoph Reiter; Volker Klein; Svetlana B Tsogoeva; Thomas Efferth
Journal:  Molecules       Date:  2018-04-06       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.